CClinicalTrials.gg
RecruitingNCT07166471GRR SingaporeUpdated Jul 15, 2026

Global Reference Ranges - Singapore

An observational study in Healthy Participants, sponsored by Perspectum. Recruiting at 1 site in Singapore. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Perspectum · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

We aim to undertake the Global Reference Range Study (GRR) to establish a set of healthy adult reference values for measures of fibroinflammation, fat and size/volumes for the liver, and other abdominal and thoracic organs to assess, compare, and if necessary, propose ethnicity specific reference ranges for these measurements.

02

Conditions studied

  • Healthy Participants
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Healthy volunteers, aged 18 years and over.

Inclusion criteria

  • Male or female at least 18 years of age
  • Self-reported healthy
  • Willing and able to give informed consent for participation in the study
  • Willing and able to undergo an MRI

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular disease as follows:

    • Myocardial infarction
    • Heart failure
    • Cardiomyopathy
    • Stroke
    • Hospital admission/discharge for unstable angina
    • Heart surgery
    • Unstable angina
    • Transient ischemic attack
  • Presence of CVD risk factors such as hypertension, hyperlipidaemia, Type 2 diabetes, BMI > 30 kg/m2, smoker (current/ex-smoker)
  • History of non-cardiac diseases related to the lungs, liver, kidneys, pancreas or spleen judged by the study investigator as therefore unsuitable to participate in the study
  • The participant may not enter the study if they have any contraindication to magnetic resonance imaging (standard MRI exclusion criteria including pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia)
  • Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the participant's ability to participate in the study
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. To determine the reference values for liver fibroinflammation in healthy adults from different ethnic groups.

    Time frame: 24 months

06

Study locations

1 of 1 sites recruiting
  • National Heart Centre Singapore
    Singapore, Singapore
    Recruiting
07

Registry details

Key details

Study ID
NCT07166471
Lead sponsor
Perspectum
Collaborators
National Heart Centre Singapore
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Jan 1, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Masliza Mahmod
Contact
masliza.mahmod@perspectum.com
001865655343
Ravi Pattanshetty
study chair · Perspectum

Oversight

FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion